Salix Tumbles With Expected "Complete Response" Letter On Xifaxan In IBS
Stock price drops 24% on news that sNDA approval will be delayed by what Salix describes as FDA's "newly expressed need for retreatment information."
Stock price drops 24% on news that sNDA approval will be delayed by what Salix describes as FDA's "newly expressed need for retreatment information."